TFS Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

TFS Capital’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,493	Closed	-$13K	–	966
2016 Q4	$13K	Sell	2,493 -4,460	-64%	-$77.2K	﹤0.01%	711
2016 Q3	$175K	Buy	6,953 +4,845	+230%	+$122K	0.04%	581
2016 Q2	$52K	Sell	2,108 -12,218	-85%	-$345K	0.01%	915
2016 Q1	$415K	Buy	14,326 +12,975	+960%	+$352K	0.06%	517
2015 Q4	$50K	Buy	+1,351	New	+$59.6K	0.01%	703
2015 Q3	–	Sell	-8,597	Closed	-$593K	–	1148
2015 Q2	$593K	Buy	+8,597	New	+$398K	0.06%	472

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TFS Capital's ANTH Position: Q1 2017 in Review

TFS Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 2,493 shares — an estimated $13K sold.

TFS Capital first reported a position in ANTH in Q2 2015 and held it in 6 quarters. The position peaked at $593K in Q2 2015. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

TFS Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 2,493 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $13K.
TFS Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 6 quarters.
TFS Capital's Anthera Pharmaceuticals, Inc. position peaked at $593K in Q2 2015.
60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.